Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
HOME > BUSINESS
BUSINESS
- Baxter Files NDA for Advate Successor in Japan
April 17, 2015
- Autologous Cultured Cartilage JACC Becomes Available Across Japan: J-TEC
April 17, 2015
- Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
- Japan’s Generic Market Projected to Top 900 Billion Yen in 2017: Fuji Keizai
April 16, 2015
- JCR Successfully Develops Blood-Brain Barrier-Passing Technology; First Application to Be Drug for Hunter Syndrome
April 16, 2015
- NIID, ID Pharma to Collaborate on Research for Therapeutic Vaccines for AIDS
April 16, 2015
- Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel
April 16, 2015
- Lixiana Gains Swiss Nod, First Approval in Europe: Daiichi Sankyo
April 16, 2015
- MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
- Hisamitsu Initiates PIII Study of Transdermal Parkinson’s Disease Treatment Ropinirole in Japan
April 16, 2015
- Eisai to Collaborate with Genomics for Drug Discovery
April 14, 2015
- Japan CSO Association Aims to Double No. of Contract Sales Reps to 8,000 by FY2020
April 14, 2015
- ViiV Healthcare Launches HIV Treatment Triumeq Combination Tablets
April 13, 2015
- Japan Vaccine Files NDA for Intradermal Influenza Vaccine
April 13, 2015
- Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
- Ethical Drug Sales Down 1.4% in February: Crecon Report
April 10, 2015
- IFN-Free, All Oral Treatment for Hepatitis C Demonstrates Impressive Response Rate
April 10, 2015
- Livalo Shows No Negative Effects on Fasting Blood Glucose Levels, HbA1c: Kowa
April 10, 2015
- Regience Partners with Keio Univ. for Joint Research of Liver Regeneration
April 10, 2015
- Announcement: 8th Annual Marketing Excellence Japan 2015 - Westin Tokyo, May 12-13
April 9, 2015
ページ
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…